Braveheart Bio (NASDAQ:BRVE) Director Buys $34,920,000.00 in Stock

Braveheart Bio, Inc. (NASDAQ:BRVE) Director Orbimed Advisors Llc purchased 1,940,000 shares of the company’s stock in a transaction on Friday, August 7th. The shares were purchased at an average price of $18.00 per share, for a total transaction of $34,920,000.00. Following the purchase, the director owned 11,901,826 shares in the company, valued at approximately $214,232,868. The trade was a 19.47% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Braveheart Bio Price Performance

Shares of BRVE stock opened at $25.97 on Friday. Braveheart Bio, Inc. has a fifty-two week low of $24.61 and a fifty-two week high of $32.00.

About Braveheart Bio

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.